{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:15369"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:15369","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Characterising the immune environment in metastatic niches in ovarian cancer","abstract":"Ovarian cancer (OvCa) continues to be a clinical challenge, with patients often presenting at late stage, and with a high occurrence of relapse and chemoresistance. The tumour microenvironment (TME) of the sites of metastasis in the omentum consists of a complex system of stromal, mesothelial, endothelial, and immune cells that echo the structure of secondary lymphoid organs and facilitate tumour spread and disease progression. This study aims to characterise the stromal cells in the TME, and further elucidate the immune-stromal interactions within the ovarian metastasis TME using C57BL/6J, DARE and IL-33 reporter murine models and human patient samples. Flow cytometry and Multiplex immunofluorescent microscopy were utilised in this study. PDPN-CD31- stromal populations expressing low amounts of FAP and CD140a are potential cancer-associated fibroblasts (CAFs) that may be involved in the direct progression of metastasis. There was also an increase in M1/M2 macrophages and cDC2 dendritic cells in metastatic omentum when compared to healthy omentum, parallel to an increase in cDC2 cells in DARE mice compared to the WT, which leads us to conclude that there is an increased immune activity within metastatic FALCs prior to chemotherapy, however more studies need to be conducted to determine if this activity is anti- or pro- high grade serous OvCa (HGSOC) tumoural proliferation.","abstract_html":"Ovarian cancer (OvCa) continues to be a clinical challenge, with patients often presenting at late stage, and with a high occurrence of relapse and chemoresistance. The tumour microenvironment (TME) of the sites of metastasis in the omentum consists of a complex system of stromal, mesothelial, endothelial, and immune cells that echo the structure of secondary lymphoid organs and facilitate tumour spread and disease progression. This study aims to characterise the stromal cells in the TME, and further elucidate the immune-stromal interactions within the ovarian metastasis TME using C57BL/6J, DARE and IL-33 reporter murine models and human patient samples. Flow cytometry and Multiplex immunofluorescent microscopy were utilised in this study. PDPN-CD31- stromal populations expressing low amounts of FAP and CD140a are potential cancer-associated fibroblasts (CAFs) that may be involved in the direct progression of metastasis. There was also an increase in M1/M2 macrophages and cDC2 dendritic cells in metastatic omentum when compared to healthy omentum, parallel to an increase in cDC2 cells in DARE mice compared to the WT, which leads us to conclude that there is an increased immune activity within metastatic FALCs prior to chemotherapy, however more studies need to be conducted to determine if this activity is anti- or pro- high grade serous OvCa (HGSOC) tumoural proliferation.","abstract_has_math":false,"creators":["Sidahmed, Heba Awad Mohammed"],"institution":"University of Birmingham","degree_name":"m_sc","degree_level":"m_sc","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-12","date_published":"2024-12","updated_at":"2026-11-19T09:32:52Z","subjects":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"person:identifier.orcid","label":"ORCID","values":["0000000272110159"],"render_values":[{"text":"0000-0002-7211-0159","href":"https://orcid.org/0000-0002-7211-0159","code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/15369/7/Sidahmed2024MScByRes.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A15369","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Sidahmed, Heba Awad Mohammed"]},{"key":"person:identifier.orcid","label":"ORCID","values":["0000000272110159"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-12-09"]},{"key":"dc:date.issued","label":"Date","values":["2024-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/15369/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_sc"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_sc"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/15369/7/Sidahmed2024MScByRes.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Ovarian cancer (OvCa) continues to be a clinical challenge, with patients often presenting at late stage, and with a high occurrence of relapse and chemoresistance. The tumour microenvironment (TME) of the sites of metastasis in the omentum consists of a complex system of stromal, mesothelial, endothelial, and immune cells that echo the structure of secondary lymphoid organs and facilitate tumour spread and disease progression. This study aims to characterise the stromal cells in the TME, and further elucidate the immune-stromal interactions within the ovarian metastasis TME using C57BL/6J, DARE and IL-33 reporter murine models and human patient samples. Flow cytometry and Multiplex immunofluorescent microscopy were utilised in this study. PDPN-CD31- stromal populations expressing low amounts of FAP and CD140a are potential cancer-associated fibroblasts (CAFs) that may be involved in the direct progression of metastasis. There was also an increase in M1/M2 macrophages and cDC2 dendritic cells in metastatic omentum when compared to healthy omentum, parallel to an increase in cDC2 cells in DARE mice compared to the WT, which leads us to conclude that there is an increased immune activity within metastatic FALCs prior to chemotherapy, however more studies need to be conducted to determine if this activity is anti- or pro- high grade serous OvCa (HGSOC) tumoural proliferation."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Characterising the immune environment in metastatic niches in ovarian cancer"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Sidahmed, Heba Awad Mohammed"],"dc:date":["2024-12-09"],"dc:date.issued":["2024-12"],"dc:description.abstract":["Ovarian cancer (OvCa) continues to be a clinical challenge, with patients often presenting at late stage, and with a high occurrence of relapse and chemoresistance. The tumour microenvironment (TME) of the sites of metastasis in the omentum consists of a complex system of stromal, mesothelial, endothelial, and immune cells that echo the structure of secondary lymphoid organs and facilitate tumour spread and disease progression. This study aims to characterise the stromal cells in the TME, and further elucidate the immune-stromal interactions within the ovarian metastasis TME using C57BL/6J, DARE and IL-33 reporter murine models and human patient samples. Flow cytometry and Multiplex immunofluorescent microscopy were utilised in this study. PDPN-CD31- stromal populations expressing low amounts of FAP and CD140a are potential cancer-associated fibroblasts (CAFs) that may be involved in the direct progression of metastasis. There was also an increase in M1/M2 macrophages and cDC2 dendritic cells in metastatic omentum when compared to healthy omentum, parallel to an increase in cDC2 cells in DARE mice compared to the WT, which leads us to conclude that there is an increased immune activity within metastatic FALCs prior to chemotherapy, however more studies need to be conducted to determine if this activity is anti- or pro- high grade serous OvCa (HGSOC) tumoural proliferation."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/15369/7/Sidahmed2024MScByRes.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/15369/"],"dc:subject":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public"],"dc:title":["Characterising the immune environment in metastatic niches in ovarian cancer"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_sc"],"dc:type.qualificationname":["m_sc"],"person:identifier.orcid":["0000000272110159"]},"updated_at":"2026-11-19T09:32:52Z"}